Given the immunohistochemical finding of HER2 (+++) in the bladder tumor, the patient began to receive Disitamab Vedotin 120 mg, an ADC targeted for HER2 and approved in China for urothelial cancers, every 3 weeks. The gene discussed is ERBB2; the disease is urinary bladder neoplasm.